Compounded Pharmacy Market is predicted to reach USD 26.1 billion at a CAGR of 7.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Compounded Pharmacy Market”.

The compounded pharmacy market is estimated to register a CAGR of 7.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global compounded pharmacy market - Fagron, Walgreen Co., JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy), Albertsons Companies, Galenic Laboratories Limited (Roseway Labs), The London Specialist Pharmacy Ltd (Specialist Pharmacy), Apollo Clinical Pharmacy, MEDS Pharmacy, Aurora Compounding, Formul8, and Fusion Apothecary.

Market Highlights

The global compounded pharmacy market is accounted to register a CAGR of 7.00% during the forecast period and is estimated to reach USD 26.1 billion by 2032.

The rise in chronic disease incidence is one of the main factors propelling the compounded pharmacy market's growth. The market is expanding due to factors such as increased life expectancy, a rise in the elderly population, and widespread use of non-sterile medications. Additionally, rising rates of medication failure, the acceptance of personalized medicine, and global drug scarcity are additional market trends for compounded pharmacies that are anticipated to support the industry's growth during the forecast period.

Access Full Report @ https://www.marketresearchfuture.com/reports/compounded-pharmacy-market-22115

Segment Analysis

The global compounded pharmacy market has been segmented into product, therapeutic area, and compounding type.

On the basis of product, the market is segmented into Topical Medications, Parenteral Medications, Oral Medications, and Other Medications. The oral medications segment was attributed to holding the largest market share in 2023. The increasing need for oral compounded medications can be ascribed to various advantages of the oral dosage form, including ease of use, painlessness, and self-administration. Segmental growth will be fueled by the easier availability of some oral pharmaceuticals, such as tablets, powder, capsules, and so on, as well as liquid preparations, such as syrups and suspensions, compared to other dosage forms.

Based on therapeutic area, the global compounded pharmacy market has been segmented into Hormone Replacement, Pain Management, Dermal Disorders, and Others. The pain management segment was expected to hold the largest market share in 2023 due to the rising incidence of chronic pain and the unfavorable effects of drugs used to treat pain that are sold commercially. In addition to combining numerous drugs in a single dose and avoiding the gastrointestinal (GI) system for individuals experiencing GI side effects, compounded pain management treatments offer several advantages.

Based on compounding type, the global compounded pharmacy market has been segmented into Pharmaceutical Ingredient Alteration, Currently Unavailable Pharmaceutical Manufacturing, Pharmaceutical Dosage Alteration, and Others. The pharmaceutical ingredient alteration segment was expected to hold the largest market share in 2023. Compounded drugs are in high demand because they can be made to address individual patient demands by modifying or altering pharmacological ingredients. PIA entails changing the ratio or concentration of a drug's active components frequently to make it more specific for a given patient.

Regional Analysis

The global compounded pharmacy market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe compounded pharmacy market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The compounded pharmacy market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World compounded pharmacy market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share for compounded pharmacy. The rise of the regional market is being driven by the unavailability of some pharmaceuticals and the existence of multiple compounded pharmacies. As per the data released by the American Pharmacists Association, there were more than 56,000 community pharmacies in the United States as of October 2021, out of which 7,500 provided advanced compounding services.

Moreover, the Europe market has been persistently growing over the forecast period. The European market is expanding as a result of both the aging population and improvements in medical care. Regulatory frameworks and guidelines further ensure the safety, quality, and uniformity of compounded pharmacy, such as those established by the European Directorate for the Quality of Medicines (EDQM), which promotes the industry's expansion.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. The primary drivers propelling the market growth are the growing need for customized drugs, the incidence of chronic illnesses on the rise, the development of the healthcare infrastructure, and the growing awareness and desire for complementary therapies.

Furthermore, the rest of the world's compounded pharmacy market is divided into the Middle East, Africa, and Latin America. The rest of world compounded pharmacy market will benefit from the presence of several market competitors, a growing number of healthcare institutions, higher healthcare spending power, and a high level of regional awareness regarding compounded pharmaceuticals. The LATAM compounded pharmacy market is anticipated to rise steadily due to the growing number of compounding pharmacies and increased awareness of the advantages of compounded drugs.

Key Findings of the Study

• The global compounded pharmacy market is expected to reach USD 26.1 billion by 2032, at a CAGR of 7.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. The rising prevalence of chronic illnesses and the expanding need for tailored medications are the main factors driving the market's expansion.


• Based on therapeutic area, the pain management segment was attributed to holding the largest market in 2023, with an approximate market share of 45–65%.


• Fagron, Walgreen Co., JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy), Albertsons Companies, Galenic Laboratories Limited (Roseway Labs), The London Specialist Pharmacy Ltd (Specialist Pharmacy), Apollo Clinical Pharmacy, MEDS Pharmacy, Aurora Compounding, Formul8 and Fusion Apothecary are the key market players.